Four New Hampshire Physicians Urge State Lawmakers to Restrict Kratom, Warning of Opioid Withdrawal Complications

Why it matters

Frontline physicians writing in an official context ahead of a state senate vote carry unusually high credibility — their clinical observations add real-world weight to debates that often focus on legislation over patient outcomes.

The big picture

New Hampshire has no statewide kratom regulations, leaving a patchwork of local action. Senate Bill 557 would restrict sales to adults 21 and older. The physicians — a mix of psychiatry residents and family medicine doctors — are reporting a consistent pattern: patients in long-term opioid recovery developing new kratom dependence, and kratom complicating clinical urine screens used to initiate buprenorphine or methadone therapy.

Key findings

• An estimated 1.7 million Americans aged 12 and older use kratom annually
• New Hampshire has no state-level kratom regulations; only two municipalities (Franklin, Nashua) have local rules
• Kratom is not detected by most standard rapid drug screenings, creating treatment complications
• Patients seeking opioid use disorder treatment who have undisclosed kratom use can experience multi-day withdrawal and hospitalization
• Adolescents may face higher risk for long-term neurobehavioral harm from kratom than adults
• Senate Bill 557, being debated in the 2026 legislative session, would restrict kratom sales to adults 21 and older

What they say

We have cared for people who developed profound depression requiring hospitalization after developing a new addiction to kratom after maintaining their recovery from opioids.

Bottom line

New Hampshire physicians warn that kratom is disrupting hard-won opioid recovery — and that the state's lack of any regulation leaves clinicians and patients without protection.